Compare Skybiotech Healt with Similar Stocks
Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at -1.44% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
Flat results in Dec 25
Risky - Negative EBITDA
Stock DNA
Garments & Apparels
INR 30 Cr (Micro Cap)
NA (Loss Making)
31
0.00%
0.83
-26.36%
3.49
Total Returns (Price + Dividend) 
Skybiotech Healt for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Kapil Cotex Ltd Stock Hits 52-Week Low Amid Continued Downtrend
Kapil Cotex Ltd, a player in the Garments & Apparels sector, recorded a fresh 52-week low of Rs.116.45 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial and operational metrics.
Read full news article
Kapil Cotex Ltd Stock Falls to 52-Week Low of Rs.126.45
Kapil Cotex Ltd, a player in the Garments & Apparels sector, has recorded a fresh 52-week low of Rs.126.45 today, marking a significant decline amid persistent downward momentum. The stock’s recent performance reflects ongoing pressures that have weighed on its valuation and market standing.
Read full news article
Skybiotech Healthcare Q3 FY26: Mounting Losses Signal Deepening Operational Crisis
Skybiotech Healthcare Limited reported a net loss of ₹0.48 crores for Q3 FY26 (Oct-Dec'25), marking a sequential deterioration of 54.84% from Q2 FY26's loss of ₹0.31 crores. The micro-cap garments and apparels company, with a market capitalisation of just ₹27.00 crores, continues to struggle with operational inefficiencies as revenue collapsed 50.00% quarter-on-quarter to ₹0.96 crores. The stock traded at ₹144.90 on February 16, 2026, down 35.54% over the past year, reflecting persistent investor concerns about the company's viability.
Read full news article Announcements 
Result- Financial Result For Quarter Ended On December 31St 2025
14-Feb-2026 | Source : BSESubmission of Un-Audited Financial Results for the Quarter ended on 31st December 2025
Board Meeting Outcome for Outcome Of Board Meeting To Considered And Approved Un-Audited Financials For The Quarter Ended On 31St December 2025
14-Feb-2026 | Source : BSEOutcome of Board Meeting to Considered and Approved Un-Audited Financials for the Quarter ended on 31st December 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On 31St December 2025
11-Feb-2026 | Source : BSESkybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve Approval of Unaudited Financial Results for the Quarter ended on 31st December 2025
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Prakashchandra Rathi (45.16%)
Ganesh Shivprasad Lahoti (4.44%)
34.88%
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is -61.90% vs 0.00% in Dec 2024
YoY Growth in quarter ended Dec 2025 is -23.08% vs -136.45% in Dec 2024
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is 100.00% vs 50.00% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -500.00% vs -100.95% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024
YoY Growth in year ended Mar 2025 is -96.10% vs 15,500.00% in Mar 2024






